



Complete Summary

TITLE

Prostate cancer: percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score.

SOURCE(S)

American Urological Association, Physician Consortium for Performance Improvement®. Prostate cancer physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Jun. 30 p. [2 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score.

RATIONALE

The initial assessment of all prostate cancer patients should include the three evaluations required in this measure.*

*The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

Tumor characteristics, including prostate-specific antigen (PSA) level and changes such as velocity and doubling time, Gleason score, and tumor stage, are predictive of cancer outcomes. Using PSA, Gleason

score, and tumor stage, risk strata have been defined that are significantly associated with PSA recurrence and cancer specific mortality. (American Urological Association [AUA])

The combination of Gleason score, PSA level, and stage can effectively stratify patients into categories associated with different probabilities of achieving a cure. In addition to considering the probability of cure, the choice of initial treatment is highly influenced by estimated life expectancy, comorbidities, potential therapy side effects, and patient preference. (National Comprehensive Cancer Network [NCCN])

PRIMARY CLINICAL COMPONENT

Prostate cancer; prostate-specific antigen (PSA); primary tumor (T) stage; Gleason score

DENOMINATOR DESCRIPTION

All patients, regardless of age, with a new diagnosis of prostate cancer (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

NUMERATOR DESCRIPTION

Patients with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Ambulatory Care
Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

TARGET POPULATION AGE

All patients, regardless of age

TARGET POPULATION GENDER

Male (only)

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

All patients, regardless of age, with a new diagnosis of prostate cancer

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

All patients, regardless of age, with a new diagnosis of prostate cancer

Exclusions

- Documentation of medical reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score (e.g., salvage therapy)
- Documentation of patient reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Clinical Condition
Encounter

DENOMINATOR TIME WINDOW

Time window is a single point in time

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Patients with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score

Exclusions

None

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Episode of care

DATA SOURCE

Administrative data
Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Measure #2: initial evaluation, new diagnoses.

MEASURE COLLECTION

[The Physician Consortium for Performance Improvement® Measurement Sets](#)

MEASURE SET NAME

[Prostate Cancer Physician Performance Measurement Set](#)

SUBMITTER

American Medical Association on behalf of the American Urological Association and Physician Consortium for Performance Improvement®

DEVELOPER

American Urological Association
Physician Consortium for Performance Improvement®

FUNDING SOURCE(S)

Unspecified

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

Ian Thompson, MD (*Co-Chair*); Steven Clauser, PhD (*Co-Chair*); Peter Albertsen, MD; Colleen Lawton, MD; Charles Bennett, MD, PhD, MPP; W. Robert Lee, MD, MS, Med; Michael Cookson, MD; Peter A. S. Johnstone, MD, FACR; Gregory W. Cotter, MD; David F. Penson, MD, MPH; Theodore L. DeWeese, MD; Stephen Permut, MD; Mario Gonzalez, MD; Howard Sandler, MD; Louis Kavoussi, MD; Bill Steirman, MA; Eric A. Klein, MD; John T. Wei, MD

Robin Hudson, MPA, American Urological Association; Beth Kosiak, PhD, American Urological Association

Trisha Crishock, MSW, American Society for Therapeutic Radiology & Oncology;
Emily Wilson, American Society for Therapeutic Radiology & Oncology

Mark Antman, DDS, MBA, American Medical Association; Kendra Hanley, MS, CHE,
American Medical Association; Karen S. Kmetik, PhD, American Medical
Association

Carol Wilhoit, MD (Health Plan Representative)

Rebecca A. Kresowik, Facilitators; Timothy F. Kresowik, MD, Facilitators

Phil Renner, MBA , National Committee for Quality Assurance

Lisa Buczkowski, RN, MS, Joint Commission on Accreditation of Healthcare
Organizations; Elvira Ryan, RN, Joint Commission on Accreditation of Healthcare
Organizations

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

Conflicts, if any, are disclosed in accordance with the Physician Consortium for
Performance Improvement® conflict of interest policy.

INCLUDED IN

Ambulatory Care Quality Alliance

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2007 Jun

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

American Urological Association, Physician Consortium for Performance
Improvement®. Prostate cancer physician performance measurement set.
Chicago (IL): American Medical Association (AMA); 2007 Jun. 30 p. [2 references]

MEASURE AVAILABILITY

The individual measure, "Measure #2: Initial Evaluation, New Diagnoses," is
published in the "Prostate Cancer Physician Performance Measurement Set." This
document and technical specifications are available in Portable Document Format
(PDF) from the American Medical Association (AMA)-convened Physician

Consortium for Performance Improvement® Web site:
www.physicianconsortium.org.

For further information, please contact AMA staff by e-mail at cqi@ama-assn.org.

NQMC STATUS

This NQMC summary was completed by ECRI Institute on November 3, 2008. The information was verified by the measure developer on December 4, 2008.

COPYRIGHT STATEMENT

© 2007 American Medical Association. All Rights Reserved.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at
<http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2009 National Quality Measures Clearinghouse

Date Modified: 1/12/2009

